U.S. Markets close in 14 mins

Genfit SA (GNFT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.39-0.21 (-3.75%)
As of 3:36PM EST. Market open.
Sign in to post a message.
  • S
    Stock
    Shorts will be forced to cover today north of 6$
  • S
    Susan
    Looked at that big rise pre-market and was excited - until I noted the big sell at the close of day yesterday that drove the price down. Good things on the horizon - patience is required as the volume is low.
  • S
    Stock
    Could see 10$ today
  • L
    Lader
    I started following "awesomestokcalerts" (Gooogle it - off course without any space or dash in between the words) and their notifications are better than anyone else.
  • e
    earline
    You need to take the next step right now to improve your trading. Get all the details at https://shr.link/Beststockalertsand don’t delay.
  • S
    SUSAN
    Maybe back from the dead today - all time low - looks like a good time to buy esp with the news
  • S
    Stock
    6$ Coming
  • S
    Stock
    Breaking 5.20$
    Bullish
  • M
    Mike
    We're about ready to go folks.
    Less than 15 minutes to open.
    Certainly love Monday's - so many possibilities.
    Bullish
  • S
    Stock
    Could see 7-9$ with this volume
  • M
    Mike
    Despite current low volume pre-h on TRVN the stock is on Robinhood's radar. On Thursday and Friday they were other places (SPI and SUNW). I'm watching small orders come through on Level II quotes (not 1 share orders - algorithyms) but around 25-50-60 shares. Look for a Robinhood bump to the upside today - I'm thinking $3.25 EOD. GLTAL.
    Bullish
  • Y
    Yahoo Finance Insights
    Genfit is up 38.66% to 5.81
  • r
    rambogalaxyman
    $GALT conversation
    Galectin commences its adaptive phase 3 trial. Genfit flunks its phase 3 trial.
    Galectin commences its adaptive phase 3 trial. Genfit flunks its phase 3 trial.
    seekingalpha.com
  • a
    adf
    Nicolaus analyst Derek Archila has a hold rating on GNFT, arguing that the stock is now likely to remain range bound until management provides an update in the fall for elafibranor in NASH.
    However, there is a glimmer of hope- elafibranor’s program in primary biliary cholangitis (PBC). Archila thinks here GNFT has solid proof-of-concept data from both an efficacy and safety perspective, and that this could provide a floor for shares.
  • A
    Aly
    12/19/2019 Show Full StoriesSend Info

    GNFT09:10 Genfit analyst commentary at Roth Capital 

    Roth says Genfit 'unlocking the power' of non-invasive diagnosis of NASH. Roth Capital analyst Yasmeen Rahimi said there is an "urgent need" for non-invasive testing in non-alcoholic steatohepatitis, or NASH, and her call with Donna Cryer of the Global Liver Institute, and Dr. Suneil Hosmane, Genfit's EVP and Global Head of Diagnostics, provided a better view into the utility and diagnostic value of the company's NIS4 NIT toolkit, which combines four biomarkers to diagnose fibrosis with high predictability. The analyst, who sees Genfit "unlocking the power of non-invasive NASH diagnosis," keeps a Buy rating and EUR70 price target on the company's shares following her expert call.
  • A
    Anonymous
    Very quiet board...

    Sometimes, still waters run deep :-)

    Anyone looking at Genfit and elafibranor for the first time (bearing in mind that the Big catalyst is the phase 3 readout in late 2019) might like to know that elafibranor was recently awarded Breakthrough Therapy status in PBC.

    Also, Barclays initiates coverage on 224 at Overweight with a PT of 55 USD (120% upside)
  • T
    Tiger
    Analysts just upgraded with 120% upside

    Check out GNFT Analyst Price Target $11.81 on TipRanks http://www.tipranks.com/ios/pages/stocks/GNFT/price-target
    Bullish
  • A
    Anonymous
    See Forbes article today: Is Genfit Primed to Win the NASH Derby?
  • T
    Terminal Gravity
    This company is starting to interest me. Recent disappointment but trading below cash. Surely their IP is worth something? Also, technicals are showing an uptick in MFI and MACD just went positive.
  • H
    HADRIAN G
    I'm trying to research this company

    I see A positive article about earnings on April 17 https://finance.yahoo.com/news/why-genfit-gnft-stock-might-124312126.html

    is elafibranor a factor in the earnings from their other operations?

    I'm assuming they will continue to operate in these other areas albeit interrupted by the Pandemic.

    What Say you?